1. Рациональная фармакотерапия ревматических заболеваний. М., 2003; 22–23.
2. Dooley M, Spencer CM, Duun CJ. Aceclofenac: a reappraisal of its use in the management of pain and rheumatic disease. Drugs 2001; 61: 1351–8
3. Yamazaki R, Kawai S, Matszaki T et al. Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into COX inhibitors. Eur J Pharmacol 1997; 25 (329): 181–7.
4. Hinz B, Rau T, Auge D et al. Aceclofenac spares cyclooxygenase 1 as a result of limited but sustained biotransformation to diclofenac. Clin Pharmacol Ther 2003; 74 (3): 222–35.
5. Alvarez-Soria MA, Largo R, Santillana J. Long term NSAID treatment inhibits COX-2 synthesis in the knee synovial membrane of patients with osteoarthritis: differential proinflammatory cytokine profile between celecoxib and aceclofenac. Ann Rheum Dis 2006; 65 (8): 998–1005.
6. Martel-Pelletier J, Cloutier J-M. Effects of aceclofenac and diclofenac on synoviale inflammatory factors in human osteoarthritis. Clin Drug Invest 1997; 14: 226–32
7. Dingle JT, Parker M. NSAID stimulation of human cartilage matrix synthesis: a study of the mechanism of action of aceclofenac. Clin Drug Invest 1997; 14: 353–62.
8. Mastbergen SC, Jansen NW, Bijlsma JW, Lafeber FP. Differential direct effects of cyclo-oxygenase-1/2 inhibition on proteoglycan turnover of human osteoarthritic cartilage: an in vitro study. Arthritis Res Ther 2006; 8 (1): R2.
9. Blanco FJ, Maneiro E, de Toro FJ et al. Effect of NSAIDs on synthesis of IL-1 receptor antagonist (IL-1Ra) by human articular chondrocytes (abstr.). Osteoarth Cartil 2000; Suppl. 8 (B): S27.
10. Yamazaki R, Kawai S, Mizushima Y et al. A major metabolite of aceclofenac, suppresses the production of interstitial procollagenase (proMMP-1 and prostromelysin-1) pro MMP-3 by human rheumatoid synovial cells. Inflam Res 2000; 49: 133–8.
11. Syggelos SA, Giannopoulou E, Gouvousis PA et al. In vitro effects of non-steroidal anti-inflammatory drugs on cytokine, prostanoid and matrix metalloproteinase production by interface membranes from loose hip or knee endoprostheses. Osteoarthritis Cartilage 2007; 15 (5): 531–42.
12. Batlle-Gualda E, Roman Ivorra J, MartТn-Mola E et al. Aceclofenac vs paracetamol in the management of symptomatic osteoarthritis of the knee: a double-blind 6-week randomized controlled trial. Osteoarth Cartil 2007; 15 (8): 900–8.
13. Pareek A, Chandanwale AS, Oak J et al. Efficacy and safety of aceclofenac in the treatment of osteoarthritis: a randomized double-blind comparative clinical trial versus diclofenac – an Indian experience. Curr Med Res Opin 2006; 22 (5): 977–88.
14. Schattenkirchner M, Milachowski KA. A double-blind, multicentre, randomised clinical trial comparing the efficacy and tolerability of aceclofenac with diclofenac resinate in patients with acute low back pain. Clin Rheumatol 2003; 22 (2): 127–35.
15. Peris F, Bird HA, Serni U et al. Treatment compliance and safety profile of aceclofenac versus standard NSAIDs in patients with common arthritic disorders: a meta-analysis. Eur J Rheum Inflam 1996; 16: 37–45.
16. Lanas A, García-RodrТguez LA, Arroyo MT et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006; 55 (12): 1731–8.
17. Laporte JR, Ibanez L, Vidal X et al. Upper gastrointestinal bleeding associated with the use of NSAIDs: newer versus older agents. Drug Saf 2004; 27 (6): 411–20.
18. Lemmel E-M, Leeb B, de Bast J et al. Patient and physician satisfaction with aceclofenac: results of the European observational cohort study. Cur Med Res Opin 2002; 18 (3): 146–53.
19. Huskisson EC, Irani M, Murray F. A large prospective open-label, multicenter SAMM study, comparing the safety of aceclofensc with diclofenac in patients with rheumatic disease. Eur J Rheum Inflam 2000; 17 (1): 1–7.
20. Yanagawa A, Endo T, Kusakari K et al. Endoscopic evaluation of aceclofenac-induced gastrointestinal mucosal damage: a double-blind comparison with diclofenac and placebo. Jap J Rheum 1998; 8: 249–59.
21. Lapeyre-Mestre M, de Castro AM, Bareille MP et al. Non-steroidal anti-inflammatory drug-related hepatic damage in France and Spain: analysis from national spontaneous reporting systems. Fundam Clin Pharmacol 2006; 20 (4): 391–5.